When administered at doses of 5.4 mg/kg or 6.4 mg/kg every three weeks, it was, in general, well tolerated and showed promising clinical efficacy in HER-2-positive breast cancer patients, as more than 90% of the patients exhibited a controlled disease, even those with a low HER-2 expression [56,57]. This evidence concerns the gene ERBB2 and breast cancer.